Shuodi Biological stock price recently dropped 14.41%, contrasting with the positive news from patent collaboration.

Shuodi Biological’s recent stock price fluctuations contrast with the positive fundamentals, mainly influenced by market sentiment, sector adjustments, and technical factors.

Recent Events

According to public information, on December 30, 2025, Shuodi Biological reached a non-exclusive patent licensing agreement with Roche and Genentech, receiving a $100 million prepayment and the right to collect low single-digit percentage royalties on future sales of Genentech’s oral GLP-1 drug CT-996. This collaboration does not restrict the company’s core pipeline development and provides non-dilutive funding support.

Recent Stock Performance

Despite the positive news, Shuodi Biological’s stock has recently declined: a range decline of 14.41%, with a volatility of 22.57%, hitting a low of $72.10. The latest trading day’s closing price was $75.70, down 3.63% for the day, while the biotech sector declined 0.45% in the same period. During the decline, trading was active, indicating significant divergence in funds.

Industry Sector Overview

Sector Adjustment: Since January 2026, the pharmaceutical and biotech sector has experienced accelerated thematic rotation, with phased profit-taking pressures emerging in innovative drug areas. Technical Correction: The stock surged to $94.90 in January driven by acquisition rumors, and the recent pullback is a normal fluctuation. Performance Pressure: The company’s Q3 2025 financial report showed zero revenue and a net loss of $65.8 million, with continued R&D investment, which may impact short-term market confidence. Competition Concerns: The CEO mentioned worries about the impact of GLP-1 generic drugs, potentially raising concerns about increased industry competition.

Institutional Views

Several brokerages remain optimistic about the long-term value, but short-term stock prices are constrained by market sentiment and liquidity changes.

The above content is compiled from public information and does not constitute investment advice.